Supernus Pharmaceuticals Q3 2025 Earnings Report

Supernus Pharmaceuticals EPS Results

• Actual EPS: N/A
• Consensus EPS: $0.35
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Supernus Pharmaceuticals Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $175.82 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Supernus Pharmaceuticals Announcement Details

• Quarter: Q3 2025
• Date: 11/3/2025
• Time: Before Market Opens
• Conference Call Date: Monday, November 3, 2025
• Conference Call Time: 4:30PM ET

Supernus Pharmaceuticals (NASDAQ:SUPN), headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients. Supernus also holds rights to Apadaz, an immediate‐release product combining benzhydrocodone and acetaminophen for short‐term pain management. In addition to these approved therapies, the company maintains a pipeline of CNS candidates in development, targeting disorders such as migraine and additional seizure subtypes.

Supernus primarily serves the U.S. market through its own commercial infrastructure and works with strategic partners to expand its international reach. The company leverages licensing and collaboration agreements to bring its products to Canada, select European markets and other regions where local regulatory approvals and distribution channels facilitate patient access.

Under the leadership of President and Chief Executive Officer Stephan John Davis III, Supernus emphasizes patient‐centric innovation and disciplined execution. Its research and development efforts are complemented by a commercialization strategy aimed at maximizing the impact of its CNS portfolio while exploring opportunities to in-license or acquire complementary assets that strengthen its position in neurological therapeutics.